TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 33087119

Group type: EXPERIMENTAL
Intervention: Tezepelumab 210 mg every 4 weeks (Q4W)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Tezepelumab 210 mg Q4W
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Tezepelumab
Number of subjects: 0
Study: 35296984

Group type: EXPERIMENTAL
Intervention: Peer recovery coach (PRC) intervention
Number of subjects: 193

Group type: COMPARATOR
Intervention: Usual care (control)
Number of subjects: 193
Study: 36007755

Group type: EXPERIMENTAL
Intervention: Tranexamic Acid (TXA)
Number of subjects: 1120858

Group type: EXPERIMENTAL
Intervention: Surgeons who utilized TXA consistently (≥90% of cases)
Number of subjects: 1120858

Group type: COMPARATOR
Intervention: Patients who did not receive TXA
Number of subjects: 1120858

Group type: COMPARATOR
Intervention: Surgeons who used TXA infrequently (≤30% of cases)
Number of subjects: 1120858
Study: 33531453

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 80
Study: 32013655

Group type: EXPERIMENTAL
Intervention: Outpatient endometrial ablation procedure
Number of subjects: 151
Study: 36316073

Group type: EXPERIMENTAL
Intervention: Data-informed stepped care (DiSC) intervention
Number of subjects: 24

Group type: COMPARATOR
Intervention: Standard care
Number of subjects: 24
Study: 33740350

Group type: EXPERIMENTAL
Intervention: Bipolar radiofrequency ablation (RFA)
Number of subjects: 33
Study: 32705817

Group type: EXPERIMENTAL
Intervention: Early treatment with vigabatrin (80–150 mg/kg/day)
Number of subjects: 80

Group type: COMPARATOR
Intervention: Conventional treatment of epileptic seizures
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Children with epilepsy (51/80; 63.8%)
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Overall population of 80 infants
Number of subjects: 80
Study: 34799110

Group type: EXPERIMENTAL
Intervention: Altered crude protein (CP) content in dietary supplements (15.3% during baseline, 19.3% during experimental)
Number of subjects: 6

Group type: COMPARATOR
Intervention: Regular supplements (13.5% during baseline, 14.8% during experimental)
Number of subjects: 6
Study: 33973327

Group type: EXPERIMENTAL
Intervention: RNase1 pretreatment 24 hours before A. hydrophila injection
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control (injected PBS)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Infection (A. hydrophila-injected)
Number of subjects: 0
Study: 34898088

Group type: EXPERIMENTAL
Intervention: Electroacupuncture stimulation of the pudendal nerve (EAP), 50 min/time, for 12 weeks
Number of subjects: 81

Group type: COMPARATOR
Intervention: Transrectal pelvic floor biofeedback combined with electrical stimulation, 50 min/time, for 12 weeks
Number of subjects: 81
Study: 34311528

Group type: EXPERIMENTAL
Intervention: EPP-AF® 400 mg/day
Number of subjects: 124

Group type: EXPERIMENTAL
Intervention: EPP-AF® 800 mg/day
Number of subjects: 124

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 124
Study: 32028389

Group type: EXPERIMENTAL
Intervention: Guided internet-assisted intervention (GIAI)
Number of subjects: 192

Group type: COMPARATOR
Intervention: Usual-care control group
Number of subjects: 192
Study: 35654363

Group type: EXPERIMENTAL
Intervention: Ranibizumab (0.5-mg or 2.0-mg) administered monthly or pro re nata over 24 months
Number of subjects: 349
Study: 34173229

Group type: EXPERIMENTAL
Intervention: Telephone follow-up calls from an ED nurse within 24 h after discharge
Number of subjects: 9836

Group type: COMPARATOR
Intervention: Scripted satisfaction survey telephone call
Number of subjects: 9836
Study: 32926835

Group type: EXPERIMENTAL
Intervention: Single-dose pneumococcal conjugate vaccine
Number of subjects: 0

Group type: COMPARATOR
Intervention: Two-dose primary series followed by a booster dose of ten-valent or 13-valent pneumococcal conjugate vaccine
Number of subjects: 0
Study: 35102732

Group type: EXPERIMENTAL
Intervention: Inspiratory plus expiratory neuromuscular electrical stimulation
Number of subjects: 120

Group type: COMPARATOR
Intervention: Diaphragm pacing (control)
Number of subjects: 120
Study: 33222689

Group type: EXPERIMENTAL
Intervention: Combined risk factor and metabolite model
Number of subjects: 9071

Group type: COMPARATOR
Intervention: Risk factors alone
Number of subjects: 9071

Group type: EXPERIMENTAL
Intervention: Independent validation in UPBEAT
Number of subjects: 9071
Study: 33219500

Group type: EXPERIMENTAL
Intervention: Therapeutic exercises and extensive pre-surgery education
Number of subjects: 60

Group type: COMPARATOR
Intervention: Control group (no therapeutic exercises)
Number of subjects: 60
Study: 33290891

Group type: EXPERIMENTAL
Intervention: Intervention group (multi‐component program including free exercise equipment at home, access to smartphone web‐app, and an online forum)
Number of subjects: 62

Group type: COMPARATOR
Intervention: Control group (usual routine)
Number of subjects: 62
Study: 35034025

Group type: EXPERIMENTAL
Intervention: L-FABP biomarker assay
Number of subjects: 154

Group type: COMPARATOR
Intervention: Control group (no L-FABP)
Number of subjects: 154
Study: 34253048

Group type: EXPERIMENTAL
Intervention: Prior lower extremity revascularization (LER)
Number of subjects: 13885

Group type: EXPERIMENTAL
Intervention: No prior lower extremity revascularization (LER)
Number of subjects: 13885
Study: 33038728

Group type: EXPERIMENTAL
Intervention: Rice Husk Compost (RHC)
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Rice Husk Biochar (RHB)
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Mycorrhiza (MR)
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: RHB + MR
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: RHC + MR
Number of subjects: 6

Group type: COMPARATOR
Intervention: No bio-fertilizers (NF) with 200 mg kg−1 SDZ
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Co-application of bio-fertilizers and SDZ (100 and 200 mg kg−1)
Number of subjects: 6

Group type: COMPARATOR
Intervention: 200 mg kg−1 SDZ with no bio-fertilizers
Number of subjects: 6
Study: 33941247

Group type: EXPERIMENTAL
Intervention: Vaxcards, a vaccination-based educational card game
Number of subjects: 13
Study: 32147571

Group type: EXPERIMENTAL
Intervention: Bupropion (300 mg/day)
Number of subjects: 422

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 422
Study: 34850160

Group type: EXPERIMENTAL
Intervention: Dapagliflozin 10 mg once daily
Number of subjects: 104

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 104

Group type: EXPERIMENTAL
Intervention: Dapagliflozin
Number of subjects: 104

Group type: COMPARATOR
Intervention: Dapagliflozin and Placebo
Number of subjects: 104
Study: 32031326

Group type: EXPERIMENTAL
Intervention: NACRT plus TME
Number of subjects: 358

Group type: COMPARATOR
Intervention: TME alone (non-NACRT)
Number of subjects: 358
Study: 35248272

Group type: EXPERIMENTAL
Intervention: IASTM
Number of subjects: 147

Group type: EXPERIMENTAL
Intervention: CKCMOB (MWM)
Number of subjects: 147

Group type: COMPARATOR
Intervention: Combination of both MT interventions
Number of subjects: 147

Group type: COMPARATOR
Intervention: Control
Number of subjects: 147

Group type: EXPERIMENTAL
Intervention: Dynamic balance (YBT-LQ™)
Number of subjects: 147
Study: 34105177

Group type: EXPERIMENTAL
Intervention: Casimersen (4, 10, 20, and 30 mg/kg weekly infusions)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study: 32828130

Group type: EXPERIMENTAL
Intervention: Ketogenic diet (KD)
Number of subjects: 80

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 80
Study: 34402872

Group type: EXPERIMENTAL
Intervention: Dapagliflozin in addition to standard care
Number of subjects: 1000

Group type: COMPARATOR
Intervention: Standard care alone
Number of subjects: 1000
Study: 35193046

Group type: EXPERIMENTAL
Intervention: Self-administered acupressure (SAA)
Number of subjects: 200

Group type: COMPARATOR
Intervention: Sleep hygiene education (SHE)
Number of subjects: 200
Study: 32572862

Group type: EXPERIMENTAL
Intervention: Anterior POEM approach
Number of subjects: 111

Group type: COMPARATOR
Intervention: Posterior POEM approach
Number of subjects: 111

Group type: COMPARATOR
Intervention: Both anterior and posterior approaches
Number of subjects: 111
Study: 32004687

Group type: EXPERIMENTAL
Intervention: HepB (CHO)
Number of subjects: 1163

Group type: COMPARATOR
Intervention: HepB (SC)
Number of subjects: 1163
Study: 35219449

Group type: EXPERIMENTAL
Intervention: i.v. ketamine (0.3 mg kg−1)
Number of subjects: 109

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 109
Study: 32975131

Group type: EXPERIMENTAL
Intervention: Exercise group (15.2 ± 4.5 exercise sessions within 2 h before each night shift)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Exercise group
Number of subjects: 24
Study: 34844295

Group type: EXPERIMENTAL
Intervention: D-Blade
Number of subjects: 41

Group type: COMPARATOR
Intervention: MAC
Number of subjects: 41
Study: 34506958

Group type: EXPERIMENTAL
Intervention: General practitioners receive feedback
Number of subjects: 699

Group type: EXPERIMENTAL
Intervention: Both patients and general practitioners receive feedback
Number of subjects: 699

Group type: COMPARATOR
Intervention: No one receives feedback
Number of subjects: 699
Study: 35505644

Group type: EXPERIMENTAL
Intervention: Tramadol via patient-controlled analgesia (PCA) pump (600 mg daily)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Intermittent tramadol administration
Number of subjects: 100
Study: 32233043

Group type: EXPERIMENTAL
Intervention: Fathers' perceived threat during deployment
Number of subjects: 104
Study: 35195722

Group type: EXPERIMENTAL
Intervention: TRACK intervention
Number of subjects: 176

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 176
Study: 34410778

Group type: EXPERIMENTAL
Intervention: Higher general social support
Number of subjects: 157

Group type: EXPERIMENTAL
Intervention: Higher family support (for mothers)
Number of subjects: 157

Group type: EXPERIMENTAL
Intervention: College education status (for mothers)
Number of subjects: 157

Group type: EXPERIMENTAL
Intervention: More partner support (for fathers)
Number of subjects: 157
Study: 34941043

Group type: EXPERIMENTAL
Intervention: HFNC-aided walking
Number of subjects: 30

Group type: COMPARATOR
Intervention: Unaided walking
Number of subjects: 30
Study: 33570975

Group type: EXPERIMENTAL
Intervention: Smoking cessation and treatment-as-usual (TAU)
Number of subjects: 538

Group type: COMPARATOR
Intervention: Placebo group (TAU)
Number of subjects: 538
Study: 33676799

Group type: EXPERIMENTAL
Intervention: Hydrogel-coated coils (0.018-inch hydrogel-coated coils, AZUR 18; Terumo Medical Corporation)
Number of subjects: 77

Group type: COMPARATOR
Intervention: Nonhydrogel group (bare platinum coils and fibered coils without hydrogel-coated coils)
Number of subjects: 77

Group type: COMPARATOR
Intervention: Nonhydrogel group
Number of subjects: 77

Group type: EXPERIMENTAL
Intervention: Hydrogel group
Number of subjects: 77
Study: 32186656

Group type: EXPERIMENTAL
Intervention: Rituximab (1000 mg IV on days 0 and 14, 500 mg at months 12 and 18) combined with short-term prednisone regimen
Number of subjects: 47

Group type: EXPERIMENTAL
Intervention: Rituximab
Number of subjects: 47

Group type: EXPERIMENTAL
Intervention: PDAI score of 45 or higher and/or persistent anti-DSG1 or anti-DSG3 antibody values at month 3
Number of subjects: 47
Study: 32878514

Group type: EXPERIMENTAL
Intervention: M2000 (mannuronic acid) 1000 mg/day (two 500 mg capsules daily)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Conventional drug (interferon beta‐1a, interferon beta‐1b)
Number of subjects: 50
Study: 33357709

Group type: EXPERIMENTAL
Intervention: HFD + OCN (3 μg/bird, 1 time/2 d, i.m.)
Number of subjects: 30

Group type: COMPARATOR
Intervention: HFD + V
Number of subjects: 30

Group type: COMPARATOR
Intervention: ND + V
Number of subjects: 30
Study: 35738693

Group type: EXPERIMENTAL
Intervention: Repeated exposure to multiple cues
Number of subjects: 74

Group type: COMPARATOR
Intervention: Exposure to multiple cues that also explicitly depicted the feared outcome (snake biting someone)
Number of subjects: 74
Study: 34525277

Group type: EXPERIMENTAL
Intervention: BNT162b2 vaccine (30-µg doses, two doses at 21 days apart)
Number of subjects: 46429

Group type: EXPERIMENTAL
Intervention: BNT162b2 vaccine
Number of subjects: 46429

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 46429
Study: 33636427

Group type: EXPERIMENTAL
Intervention: 20% albumin and crystalloid
Number of subjects: 304

Group type: COMPARATOR
Intervention: Crystalloid alone
Number of subjects: 304
Study: 35698043

Group type: EXPERIMENTAL
Intervention: Individual counseling based on GATHER principles (4 sessions, 45-60 minutes each for 2 weeks)
Number of subjects: 82

Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 82

Group type: EXPERIMENTAL
Intervention: Individual counseling based on GATHER principles
Number of subjects: 82
Study: 34726606

Group type: EXPERIMENTAL
Intervention: Spherical video‐based virtual reality (SVVR) training
Number of subjects: 68

Group type: COMPARATOR
Intervention: Control group (no training)
Number of subjects: 68
Study: 32992943

Group type: EXPERIMENTAL
Intervention: Vibration group (n = 25)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Placebo group (n = 25)
Number of subjects: 50
Study: 36331844

Group type: EXPERIMENTAL
Intervention: Non-cultured epidermal cell suspension
Number of subjects: 30

Group type: COMPARATOR
Intervention: Automated epidermal harvesting system
Number of subjects: 30
Study: 33688916

Group type: EXPERIMENTAL
Intervention: Alopecia severity (varied degrees of alopecia)
Number of subjects: 2015
Study: 34954440

Group type: EXPERIMENTAL
Intervention: Detailed length-marked VCs (dVCs)
Number of subjects: 137

Group type: COMPARATOR
Intervention: Simplified length-marked VCs (sVCs)
Number of subjects: 137

Group type: EXPERIMENTAL
Intervention: Smartphone-assisted guidance technique (GA)
Number of subjects: 137

Group type: COMPARATOR
Intervention: Standard freehand technique (FH)
Number of subjects: 137
Study: 33905913

Group type: EXPERIMENTAL
Intervention: Guided self-help exercise program (ITwC) including flexibility, range-of-motion, and lymphedema exercises, and a self-care education program
Number of subjects: 92

Group type: COMPARATOR
Intervention: Self-care education program only (Control)
Number of subjects: 92

Group type: EXPERIMENTAL
Intervention: Sensitivity analysis using QLU-C10D to calculate QALYs
Number of subjects: 92

Group type: EXPERIMENTAL
Intervention: Sensitivity analysis using SwalQol
Number of subjects: 92
Study: 32442384

Group type: EXPERIMENTAL
Intervention: 20 min of stationary cycling at moderate intensity (65%‐75% maximal heart rate)
Number of subjects: 15

Group type: COMPARATOR
Intervention: Rest
Number of subjects: 15
Study: 35352415

Group type: EXPERIMENTAL
Intervention: hCG (5000 IU, iv)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Control (normal saline)
Number of subjects: 12
Study: 33550562

Group type: EXPERIMENTAL
Intervention: Insomnia
Number of subjects: 930

Group type: EXPERIMENTAL
Intervention: Excessive daytime sleepiness
Number of subjects: 930

Group type: EXPERIMENTAL
Intervention: Poor sleeping (PSQI > 5)
Number of subjects: 930

Group type: EXPERIMENTAL
Intervention: Age 45-54 years
Number of subjects: 930

Group type: EXPERIMENTAL
Intervention: Age ≥ 55 years
Number of subjects: 930

Group type: EXPERIMENTAL
Intervention: Overweight or obese
Number of subjects: 930

Group type: EXPERIMENTAL
Intervention: Underweight
Number of subjects: 930

Group type: EXPERIMENTAL
Intervention: Female gender
Number of subjects: 930

Group type: EXPERIMENTAL
Intervention: Divorced status
Number of subjects: 930
Study: 34882176

Group type: EXPERIMENTAL
Intervention: Nightly LBNP (-20 mm Hg)
Number of subjects: 10

Group type: COMPARATOR
Intervention: No LBNP
Number of subjects: 10
Study: 33499911

Group type: EXPERIMENTAL
Intervention: Home-based health education intervention delivered by trained female community health volunteers (FCHVs) for 12 months
Number of subjects: 884

Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 884
Study: 32507144

Group type: EXPERIMENTAL
Intervention: Osteopathic manipulative treatment associated with exercises (OMT/EG)
Number of subjects: 90

Group type: COMPARATOR
Intervention: Exercises group (EG)
Number of subjects: 90
Study: 37086227

Group type: EXPERIMENTAL
Intervention: Colchicine 0.6 mg orally twice daily for 7 days starting immediately post-procedure (group B)
Number of subjects: 139

Group type: COMPARATOR
Intervention: Standard of care (no postprocedure prophylaxis, group A)
Number of subjects: 139

Group type: EXPERIMENTAL
Intervention: Colchicine 0.6 mg orally twice daily for 7 days (group B)
Number of subjects: 139

Group type: COMPARATOR
Intervention: Standard of care (group A)
Number of subjects: 139

Group type: EXPERIMENTAL
Intervention: Cavotricuspid isthmus ablation
Number of subjects: 139

Group type: EXPERIMENTAL
Intervention: Pulmonary vein isolation
Number of subjects: 139
Study: 34284348

Group type: EXPERIMENTAL
Intervention: Nitrate-rich vegetables (NRV)
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Beetroot juice (BRJ)
Number of subjects: 18

Group type: COMPARATOR
Intervention: Nitrate-depleted beetroot juice (placebo)
Number of subjects: 18
Study: 34798038

Group type: EXPERIMENTAL
Intervention: Etrolizumab 105 mg subcutaneously once every 4 weeks
Number of subjects: 397

Group type: COMPARATOR
Intervention: Infliximab 5 mg/kg intravenously at 0, 2, and 6 weeks, then every 8 weeks for 52 weeks
Number of subjects: 397

Group type: EXPERIMENTAL
Intervention: Etrolizumab
Number of subjects: 397

Group type: COMPARATOR
Intervention: Infliximab
Number of subjects: 397
Study: 33358809

Group type: EXPERIMENTAL
Intervention: Pair housing (PR; 2 hutches with common outdoor space)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Individual housing (INDV; 1 hutch plus outdoor space)
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Pair housing (PR)
Number of subjects: 24
Study: 32366785

Group type: EXPERIMENTAL
Intervention: F‐florbetapir PET
Number of subjects: 57

Group type: EXPERIMENTAL
Intervention: F‐FDG PET
Number of subjects: 57
Study: 34289782

Group type: EXPERIMENTAL
Intervention: Feedback Display B with 100% frequency (100B)
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Feedback Display A with 50% frequency (50A)
Number of subjects: 18

Group type: COMPARATOR
Intervention: No feedback (0FB)
Number of subjects: 18
Study: 33899093

Group type: EXPERIMENTAL
Intervention: Amiodarone
Number of subjects: 245

Group type: EXPERIMENTAL
Intervention: Flecainide
Number of subjects: 245

Group type: EXPERIMENTAL
Intervention: Sotalol/Dronedarone
Number of subjects: 245

Group type: EXPERIMENTAL
Intervention: Class I/III AADs (overall)
Number of subjects: 245

Group type: COMPARATOR
Intervention: Control group (targeted therapy)
Number of subjects: 245
Study: 33683586

Group type: EXPERIMENTAL
Intervention: Substrate with organic compost (S1) at 50% effluent dose
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Substrate with water hyacinth fibers (S2)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Substrate with organic compost (S1)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control treatment at doses 25% and 50% in S1
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: All treatments
Number of subjects: 0
Study: 32585700

Group type: EXPERIMENTAL
Intervention: Lemborexant 5 mg (LEM5)
Number of subjects: 949

Group type: EXPERIMENTAL
Intervention: Lemborexant 10 mg (LEM10)
Number of subjects: 949

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 949
Study: 33826913

Group type: EXPERIMENTAL
Intervention: semaglutide
Number of subjects: 0

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 0
Study: 32164679

Group type: EXPERIMENTAL
Intervention: Bouldering psychotherapy (BPT)
Number of subjects: 133

Group type: COMPARATOR
Intervention: Home-based supervised exercise programme (EP)
Number of subjects: 133
Study: 32283762

Group type: EXPERIMENTAL
Intervention: Curcumin supplementation (180 mg/day for 12 weeks)
Number of subjects: 0
Study: 34706398

Group type: EXPERIMENTAL
Intervention: Clinician VR (CVR)
Number of subjects: 79

Group type: EXPERIMENTAL
Intervention: Trainee VR (TVR)
Number of subjects: 79

Group type: COMPARATOR
Intervention: Trainee RP (TRP)
Number of subjects: 79
Study: 33459249

Group type: EXPERIMENTAL
Intervention: Subcuticular sutures
Number of subjects: 240

Group type: COMPARATOR
Intervention: Interrupted sutures
Number of subjects: 240
Study: 32710498

Group type: EXPERIMENTAL
Intervention: BEACOPP
Number of subjects: 1227

Group type: COMPARATOR
Intervention: ABVD
Number of subjects: 1227
Study: 32122161

Group type: EXPERIMENTAL
Intervention: Cognitive Therapy (CT)
Number of subjects: 182

Group type: EXPERIMENTAL
Intervention: Interpersonal Psychotherapy (IPT)
Number of subjects: 182

Group type: COMPARATOR
Intervention: Waitlist Control
Number of subjects: 182
Study: 35802960

Group type: EXPERIMENTAL
Intervention: Smartphone-enhanced nurse-facilitated self-care intervention
Number of subjects: 210

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 210
Study: 34358271

Group type: EXPERIMENTAL
Intervention: Deliberate self-poisoning (DSP) cases with DSM-IV TR Axis-I & II disorders
Number of subjects: 439

Group type: EXPERIMENTAL
Intervention: Deliberate self-poisoning (DSP) cases
Number of subjects: 439

Group type: EXPERIMENTAL
Intervention: Deliberate self-poisoning (DSP) cases with depressive episode
Number of subjects: 439

Group type: EXPERIMENTAL
Intervention: Deliberate self-poisoning (DSP) cases, males aged >= 30 years with alcohol use disorder
Number of subjects: 439

Group type: EXPERIMENTAL
Intervention: Deliberate self-poisoning (DSP) cases, females aged 10-19 years with borderline personality traits
Number of subjects: 439

Group type: EXPERIMENTAL
Intervention: Deliberate self-poisoning (DSP) cases, older participants with depressive disorder and alcohol-related disorders
Number of subjects: 439

Group type: COMPARATOR
Intervention: Controls (age, sex, and residential area matched)
Number of subjects: 439
Study: 32548299

Group type: EXPERIMENTAL
Intervention: Tumor Sphericity (SPH) at pretreatment (T0)
Number of subjects: 220

Group type: EXPERIMENTAL
Intervention: Tumor Sphericity (SPH) at early-treatment (T1)
Number of subjects: 220

Group type: EXPERIMENTAL
Intervention: Receiver Operating Characteristic Curve (AUC) at T0
Number of subjects: 220

Group type: EXPERIMENTAL
Intervention: Receiver Operating Characteristic Curve (AUC) at T1
Number of subjects: 220

Group type: EXPERIMENTAL
Intervention: Receiver Operating Characteristic Curve (AUC) for HR-/HER2+ subtype at T0
Number of subjects: 220

Group type: EXPERIMENTAL
Intervention: Receiver Operating Characteristic Curve (AUC) for HR-/HER2+ subtype at T1
Number of subjects: 220
Study: 36735054

Group type: EXPERIMENTAL
Intervention: Denosumab 60 mg (Prolia, Amgen Inc.) administered at baseline, 6, and 12 months
Number of subjects: 14

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 14